Biotech

All Articles

Actinogen's cortisol blocker neglects period 2 clinical depression study

.Actinogen Medical's cortisol blocker has actually missed the key endpoint of a period 2 research in...

Bivictrix decides going exclusive only way to take ADC in to medical clinic

.Antibody-drug conjugates (ADCs) have been at the center of a lot of a billion-dollar biobuck licens...

TPG tops up funds to $580M for expenditures all over lifestyle sciences

.Possession supervisor TPG, which has actually supported biotechs like Sionna Therapies as well as S...

Merck ceases period 3 TIGIT test in lung cancer for impossibility

.Merck &amp Co.'s TIGIT plan has actually endured yet another drawback. Months after shuttering a pe...

After a difficult year, Exscientia folds in to Recursion

.After a year defined through pipeline cuts, the shift of its CEO and discharges, Exscientia is goin...

Cullinan, after $25M bargain, return bispecific to Harbour

.Cullinan Therapeutics was thrilled enough along with Harbour BioMed's bispecific immune activator t...

A deeper take a look at Brutal Biotech's Tough 15

.In this full week's episode of "The Best Pipe," we're diving in to Brutal Biotech's annual Intense ...

Lilly encounters period 2 failure of tau-targeting med

.The confetti is still soaring from Eli Lilly's event celebrating the commendation of Alzheimer's il...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our summary of substantial management hirings, firings as w...

Lykos will certainly talk to FDA to reexamine its decision adhering to being rejected of MDMA treatment for post-traumatic stress disorder

.Adhering to an inadequate presenting for Lykos Therapies' MDMA applicant for post-traumatic stress ...